S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder CancerLung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersNivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal CancerPegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCombination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch RepairAtezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant MesotheliomaCisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung CancerErlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerIpilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Advanced MelanomaDabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by SurgeryA Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast CancerThe (PIVOTAL) StudyRadiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent SurgeryA Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast CancerS0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast CancerSorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or CholangiocarcinomaLenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaDasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland TumorsRuxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid LeukemiaChemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder CancerGemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract CancersGenetic Analysis of Blood and Tissue Samples From Participants With Advanced CancerCarboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryTesting Ramipril to Prevent Memory Loss in People With GlioblastomaFinancial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing TreatmentPembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseEfficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per DayDigital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast CancerPemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung CancerAntiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by SurgeryPazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After SurgeryTestosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor TreatmentDocetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast CancerHormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate CancerS1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CancerVeliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerAzacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaTivantinib in Treating Patients With Metastatic Prostate CancerS1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib HydrochlorideRituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
P6153
Q58407874-BD50D624-B400-4C95-BDBF-971CCC4D26BEQ58407878-6C53E432-84A6-442E-A389-15F16ABE147AQ58845122-AB6AD9E3-76F7-4C92-A5C2-A1D137E15471Q58845627-88ED0A49-982F-457C-A44C-A09BA60D7BC8Q58845885-928312E9-A0E2-4A71-93C6-8474C1AD41EEQ58846476-43F2505D-CEFF-4447-98D1-B1EAC7C93A93Q58846742-4B7351C4-1503-4C7A-BF3B-A922DA8F25BAQ61713087-7852E7D1-9E87-4390-A205-809433D06ED3Q61713089-6FF18817-5686-4D33-8DCE-D7E7F19D1291Q61864729-DC4C3952-B444-4DEB-917A-8EE7063B5120Q61918404-8E7CC8D9-0B15-4AE1-AAE2-C9D9C239D6ADQ61924687-22D1C714-05F6-4CF7-9BB5-B71907F569C7Q61936010-EA93DFCD-A8AE-4819-B14D-E5EFE8CBAC44Q61936011-C07608E2-F471-47A2-AC55-7D4486453672Q61936449-313C5F5C-18D7-4A66-AB0C-FE177CB39361Q61936900-85308C69-7DFA-4B5E-9736-D0151ADD316EQ61938122-CBF422EB-DE4D-4C0E-9F3B-8F4AFAAD7448Q61981563-29C49304-EE4F-4489-918F-B8A6762AC93FQ62025050-EBAB1EBC-B1B6-42E2-B1C6-5112FA024CFCQ62030911-AF9DA960-8D33-4478-AF35-24DA1CF842F7Q62031551-569B2956-4113-499B-88DA-7B735F87A295Q62042674-9DE19D09-10F1-4F77-ABEA-D9B6958B2DCDQ62105307-058D9913-78F1-4483-BEDC-B5EBF50B22B7Q62814121-F7F3EA05-9943-43AC-9382-E3A39447E629Q62817334-C38DFA27-F20E-48A2-AB10-AC0EFBFC6750Q62817877-0BF55688-509E-464B-AEE7-87DD2C8948A4Q63011692-92272B41-63BC-4F47-803E-36C840D5D580Q63011965-C5B95098-7352-4036-8E2D-029EEFF3C090Q63063018-50C98EE9-8583-43C2-A3FC-E4C3BA332227Q63229064-E694A5F9-9A45-4E87-888A-9433167C4D5CQ63315791-B6A201CC-634A-48EE-AEA1-33277A3C3E86Q63316114-6F1C7E9E-534D-45F8-90B3-E4B60ADE908BQ63316568-29843007-8CD7-4F5D-9E54-A61944F08853Q63316806-D225E1E3-974B-4F45-B2AE-0F3E8F4F74E9Q63318503-16F498A5-0DEE-4F1C-84B8-D69F0BC0D64BQ63319168-7A950FD7-159B-4FD9-B464-AA07A4439432Q63319699-47EBA13C-FE37-4AB2-B408-F7C9ABF4CFD9Q63320732-E32FC429-9AB5-41B4-95B5-87DFBEA01511Q63322843-AB42D62C-DB7C-4FEE-BD44-05E530B4A34EQ63322920-2696DCB6-A38E-433F-BEE3-2EB363AD1FBC
P6153
description
griya sakit
@jv
hospital d'Estaos Xuníos
@ast
hospital in Illinois, United States
@en
hôpital
@fr
rumah sakik
@min
rumah sakit di Amerika Serikat
@id
rumoh sakét
@ace
ziekenhuis in Decatur, Verenigde Staten van Amerika
@nl
مستشفى
@ar
병원
@ko
name
Decatur Memorial Hospital
@en
type
label
Decatur Memorial Hospital
@en
prefLabel
Decatur Memorial Hospital
@en
P131
P213
0000 0004 0394 770X
P2427
grid.433546.3
P3417
Decatur-Memorial-Hospital
P571
1916-01-01T00:00:00Z
P625
Point (-88.961327 39.86685)